Back to search results

Zavegepant for Migraine in Children Aged 6-11

This study is looking for children aged 6 to 11 who experience migraines. Its main goal is to understand how the body processes Zavegepant (PF-07930207), a medicine given as a nasal spray, and to check its safety. Researchers will measure how much of the medicine is in the blood and how long it takes for the body to absorb and remove it. You can join if you've had migraines for at least six months and weigh more than 15 kilograms. All participants will receive one dose of Zavegepant, with the amount based on their weight.

Study design
This interventional study plans to enroll 16 participants. All participants will receive Zavegepant as a nasal spray.
What's involved
Participants will receive a single nasal spray dose of Zavegepant. Blood samples will be taken at specific times on Day 1 and Day 2 to measure the medicine's levels.
Compensation
Not stated in the trial record.
Follow-up
Blood samples are collected on Day 1 and Day 2 to measure drug levels.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06995729

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Recruiting
PHASE1Ages 6–11InterventionalTreatment
Pfizer
~16 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Zavegepant

At a glance

Recruiting sites
9 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Observed Plasma Concentration (Cmax)
Measured over Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours
+2 more outcomes measured

Conditions

Acute Treatment of Migraine

Explore related trials

Migraine

Where it's being run

13 sites across 10 states
North Carolina3
Utah2
Arkansas1
District of Columbia1
Georgia1
Minnesota1
Nebraska1
New York1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

Pfizer CT.gov Call Center
[email protected]
1-800-718-1021
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Clinically significant depression (Promis Parent Proxy SF 2.0 Depressive Scale T score ≥70)
Suicidal ideation and behaviour (C-SSRS: any "yes" to items 2 to 5 or any "yes" to suicide behaviours) 6. Serum Total bilirubin \>1.5 × ULN (Upper Limit of Normal), AST (Aspartate Transferase) or ALT (Alanine Transaminase) \>2 × ULN 7. Abnormal ECG (Electrocardiogram) at screening visit

What this trial measures

  • Maximum Observed Plasma Concentration (Cmax)Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours

    Cmax is defined as the maximum observed plasma concentration of zavegepant after administration of a single dose

  • Time to Reach Maximum Observed Plasma Concentration (Tmax)Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours

    Tmax is defined as the time to reach maximum observed plasma concentration

  • Area Under the Curve From Time Zero to infinity.Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours

    AUC (0 - inf) is defined as area under the concentration-time curve from time 0 to infinity.